• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Psoriatic Arthritis News / Ustekinumab, an Inhibitor of IL 12/23, Studied in Patients with Psoriatic Arthritis

Ustekinumab, an Inhibitor of IL 12/23, Studied in Patients with Psoriatic Arthritis

April 3, 2009 By Arthritis Center

Arthritis Mutilans in a Patient with Psoriatic Arthritis
Arthritis Mutilans in a Patient with Psoriatic Arthritis

There are currently no biologic treatment options available for patients with psoriatic arthritis (PsA) who are non-responsive to traditional non-biologic DMARDs and TNF inhibitors.  Interleukins (IL) 12 and 23 have been implicated in the pathogenesis of plaque psoriasis.  A humanized monoclonal antibody directed against these cytokines, ustekinumab, has demonstrated efficacy in the treatment of psoriasis in late phase trials.  IL 12/23 is also implicated in the mechanism of joint damage in PsA.  Here, Gottlieb et al (Lancet 2009; 373: 633) reports the results of a phase II randomized placebo controlled clinical trial of ustekinumab in patients with PsA.

Methods

Adults with active PsA with plaque psoriasis (defined as 3 or more swollen and tender joints and either CRP > 15 mg/L or morning stiffness ≥ 45 minutes) from 24 centers in North America and Europe were randomized to receive ustekinumab 90 mg (later changed to 63 mg) as a subcutaneous injection in a 1:1 cross-over design.  Patients randomized to receive ustekinumab initially received active drug weekly for the first 4 weeks, then placebo at weeks 12 and 16.  Patients randomized to the delayed group received placebo weekly for the first 4 weeks, then active drug at weeks 12 and 16.  Patients were required to have had an inadequate response to prior treatment (DMARDs, TNF inhibitors, or NSAIDs) and could be receiving concomitant stable methotrexate (up to 25 mg per week), corticosteroids (up to 10 mg per week), or NSAIDs.  TNF inhibitors and topical psoriasis drugs required discontinuation for set periods prior to randomization.  Enrollment was stratified to include no more than 20% of patients with prior exposure to TNF inhibitors, with equal allotment to each group.

ACR 20 response at week 12 was the primary efficacy endpoint.  Secondary endpoints included ACR 50 and 70 responses, HAQ, and improvements in skin psoriasis using the psoriasis area and severity index (PASI).

Results

A total of 146 patients were enrolled (n=76 to receive ustekinumab and n=70 to placebo).  There were 2 withdrawals before week12 in the ustekinumab group compared to 7 in the placebo group.  Of the 63 remaining patients who received initial placebo, 57 received ustekinumab in the cross-over phase.  A total of 63 of the patients who initially received ustekinumab completed through week 36 while 52 of the initially placebo treated patients completed through week 36.

Approximately 45% of the enrolled patients were women with a mean age of approximately 49 years and a median duration of disease of approximately 5 years.  Patients had a median of approximately 8 swollen and 18 tender joints at enrollment and median HAQ scores of 0.8 indicated moderate disability for the groups.  Prior DMARDs were used in about two-thirds and no patients were currently using corticosteroids.  Approximately 25% had used biologics in the past, although about half of these were biologics used primarily to treat psoriasis.

Efficacy Endpoints at 12 weeks
Ustekinumab
N=76
Placebo
N=70
p
ACR20 42% 14% 0.0002
ACR50 25% 7% 0.0038
ACR70 11% 0% 0.0055
Change in HAQ (median) -0.25 0.00 0.0005
PASI75 52% 5% <0.0001

By week 12, any adverse events (AEs) were reported in 62% of patients, with 3% discontinuing due to AEs.  No serious adverse events (SAEs) were noted by week 12 in ustekinumab treated patients compared to 3 in the placebo group.  By week 36, 6 ustekinumab treated patients reported SAEs (one each of syncope, respiratory tract infection, hemorrhagic stroke, congestive heart failure/myocardial infarction/hypertension, chest pain, gastric ulcer hemorrhage).  One recurrent basal cell carcinoma was reported in a ustekinumab treated patient.

Conclusions

In this phase II clinical trial, ustekinumab was superior to placebo in controlling the signs and symptoms of psoriatic arthritis.  No major safety signals were detected.

Editorial Comment

New therapies are needed to treat patients with refractory psoriatic arthritis, and the availability of a biologic with a mechanism differing from the TNF inhibitors would be a welcome addition to the rheumatologist’s armamentarium.  Although this is a relatively small trial and designed mainly to determine safety rather than efficacy, the efficacy of ustekinumab for arthritis actually seems rather modest, with 58% of treated patients failing to have a minimal clinical response and 75% failing to have a meaningful response (i.e. ACR50).  Whether these responses would improve with dosing greater than 4 weeks remains to be determined.  However, improvements in skin psoriasis are fairly robust (as has been shown in other trials).  The lack of safety signals in the trial is reassuring, but larger trials with more prolonged administration of the agent are required for reassurance.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy